TY - JOUR
AU - Swanson, Phillip A.
AU - Padilla, Marcelino
AU - Hoyland, Wesley
AU - McGlinchey, Kelly
AU - Fields, Paul A.
AU - Bibi, Sagida
AU - Faust, Saul N.
AU - McDermott, Adrian B.
AU - Lambe, Teresa
AU - Pollard, Andrew J.
AU - Durham, Nicholas M.
AU - Kelly, Elizabeth J.
PY - 2021
DA - November
TI - AZD1222/ ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein specific T H 1 response with a diverse TCR repertoire
JO - Science Translational Medicine
VL - 13
IS - 620
DO - https://doi.org/10.1126/scitranslmed.abj7211
AB - AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in clinical trials and real-world studies. We characterized CD4+ and CD8+ T cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells from 296 unique vaccine recipients aged 18 to 85 years who enrolled in the phase 2/3 COV002 trial. Total spike protein–specific CD4+ T cell helper type 1 (TH1) and CD8+ T cell responses were increased in AZD1222-vaccinated adults of all ages after two doses of AZD1222. CD4+ TH2 responses after AZD1222 vaccination were not detected. Furthermore, AZD1222-specific TH1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups. T cell receptor β (TCRβ) sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for both AZD1222-induced CD4+ and CD8+ T cell responses. Overall, AZD1222 vaccination induced a polyfunctional TH1-dominated T cell response, with broad CD4+ and CD8+ T cell coverage across the SARS-CoV-2 spike protein.
PB - American Association for the Advancement of Science
UR - http://eprints.gla.ac.uk/260585/
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
ER